Search Within

Alison Michele Schram

Formats
  1. Journal Article (60)
  2. Meeting Abstract (59)
  3. Editorial (3)
  4. Review (3)
  5. Miscellaneous (2)
  6. Research Letter (1)
Groups
  1. Department of Medicine (128)
  2. Early Drug Development Service (128)
  3. Gynecologic Medicine Service (128)
  4. Hematology-Oncology Fellows (128)
  5. Solid Tumor Oncology Division (128)
  6. GSK Faculty (54)

More Groups

People
  1. David Hyman (49)
  2. Alexander Drilon (46)
  3. Michael Berger (24)
  4. Barry Taylor (16)
  5. Marc Ladanyi (16)
  6. Helen Won (14)

More People

Years
  1. 2025 (10)
  2. 2024 (18)
  3. 2023 (9)
  4. 2022 (16)
  5. 2021 (17)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Annals of Oncology (13)
  3. Cancer Research (13)
  4. Cancer Discovery (9)
  5. JCO Precision Oncology (6)
  6. Clinical Cancer Research (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (36)
  2. American Association for Cancer Research (30)
  3. Oxford University Press (14)
  4. Nature Publishing Group (12)
  5. Elsevier Inc. (8)
  6. American Medical Association (3)

More Publishers

Results (128)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PYNNACLE phase II clinical trial protocol: Rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation
    Journal Article

    Schram, A. M.; Fellous, M.; LeDuke, K.; Schmid, A.; Dumbrava, E. E.
    Future Oncology (2025)

    Fulltext@MSK | Save
  • A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors
    Journal Article

    Schram, A. M.; Takebe, N.; Chen, A.; Zhou, Q.; Iasonos, A.; Silber, J.; Reynolds, M.; Hussain, S.; Gavriliuc, M.; Smyth, L. M.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Clinical utility and prognostic implications of circulating cell-free DNA in biliary tract cancer
    Journal Article

    Cowzer, D.; Darmofal, M.; Seier, K.; Thummalapalli, R.; Walch, H.; El Dika, I.; Khalil, D. N.; Park, W.; Dhyani, A.; Yaqubie, A.; more...
    JCO Precision Oncology (2025)

    Fulltext@MSK | Save
  • Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2-advanced breast cancer: ReDiscover trial
    Meeting Abstract

    Sammons, S. L.; Manich, C. S.; Italiano, A.; Schram, A. M.; Ortega, P. T.; Schott, A. F.; Guerrero, A.; Aix, S. P.; Nanda, R.; Wisinski, K. B.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Beamion PANTUMOR-1: A phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2 -mutated or overexpressed/amplified solid tumors
    Meeting Abstract

    Schram, A. M.; Clay, T. D.; Prenen, H.; Park, J. J.; Lunger, L.; Hussain, J.; Maier, D.; Kitano, S.; Dumbrava, E. E.; Kim, H. D.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Restoration of the tumor suppressor function of Y220C-mutant p53 by rezatapopt, a small-molecule reactivator
    Journal Article

    Puzio-Kuter, A. M.; Xu, L.; McBrayer, M. K.; Dominique, R.; Li, H. H.; Fahr, B. J.; Brown, A. M.; Wiebesiek, A. E.; Russo, B. M.; Mulligan, C. L.; more...
    Cancer Discovery (2025)

    Fulltext@MSK | Save
  • PYNNACLE phase II assessing rezatapopt in patients with advanced solid tumors, including lung cancer, harboring a TP53 Y220C mutation
    Meeting Abstract

    De Miguel, M. J.; Dumbrava, E. E.; Body, A.; Eberst, L.; Frenel, J. S.; Italiano, A.; Johnson, M. L.; Kaczmar, J.; Kummar, S.; Lorusso, P. M.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Retrospective analysis of BRCA-altered uterine sarcoma treated with poly(ADP-ribose) polymerase inhibitors
    Journal Article

    Rao, M.; Merrill, M.; Troxel, M.; Chiang, S.; Momeni-Boroujeni, A.; Hensley, M. L.; Schram, A. M.
    JCO Precision Oncology (2025)

    Fulltext@MSK | Save
  • A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors
    Journal Article

    Schram, A. M.; Boni, V.; Adjei, A. A.; Olszanski, A. J.; Vieito, M.; Francis, J. H.; Kurman, M.; Ahsan, J. M.; Tomkinson, B.; Garralda, E.
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Efficacy of zenocutuzumab in NRG1 fusion-positive cancer
    Journal Article

    Schram, A. M.; Goto, K.; Kim, D. W.; Macarulla, T.; Hollebecque, A.; O'Reilly, E. M.; Ou, S. H. I.; Rodon, J.; Rha, S. Y.; Nishino, K.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save